文献速递神经肌肉病

重症肌无力损害指数:反应性、有意义变化与相对效率

Myasthenia Gravis Impairment Index: Responsiveness, meaningful change, and relative efficiency.
PubMed 文献 · Neurology · 2017-11-03

本研究纳入95例接受泼尼松、IVIg或PLEX治疗的重症肌无力患者及54例对照,评估MGII的反应性、有意义变化及相对效率。结果显示MGII对三种治疗均有反应性,眼肌与全身症状对不同治疗反应存在差异,个体MDC95为9.1,MID个体为5.5、组为8.1,相对效率优于其他量表。

要点

  • MGII对泼尼松、IVIg和PLEX治疗均显示反应性。
  • 眼肌症状对泼尼松反应更明显,全身症状对IVIg/PLEX反应更明显。
  • MGII个体MID为5.5分,组MID为8.1分,相对效率优于对照量表。

核心结论

  • MGII对泼尼松、IVIg和PLEX治疗的重症肌无力患者具有反应性。
  • 眼肌与全身症状对不同治疗类型的反应存在差异。
  • MGII相对效率高于对照量表,适用于临床试验。

研究设计与样本

  • 纳入95例接受泼尼松、IVIg或PLEX治疗的患者和54例对照。
  • 在基线和治疗后3-4周使用MGII及其他量表评估。
  • 采用锚定法基于患者印象变化评估有意义变化,并计算MDC和MID。

主要发现

  • 治疗组MGII评分变化高于对照组(ANCOVA p < 0.001)。
  • 眼肌域泼尼松效应量0.67,IVIg/PLEX效应量0.13(ANCOVA p = 0.001)。
  • 全身域IVIg/PLEX效应量0.50,泼尼松效应量0.22(ANCOVA p = 0.07)。
  • MGII总分个体MDC95为9.1,个体MID为5.5,组MID为8.1。
  • 相对效率比均大于1,支持MGII优于对照量表。

关键数值与推荐

  • MGII个体MDC95为9.1。
  • MGII个体MID为5.5。
  • MGII组MID为8.1。
  • 眼肌域效应量:泼尼松0.67,IVIg/PLEX 0.13(ANCOVA p = 0.001)。
  • 全身域效应量:IVIg/PLEX 0.50,泼尼松0.22(ANCOVA p = 0.07)。

临床怎么用

  • MGII可用于评估重症肌无力患者对泼尼松、IVIg或PLEX的治疗反应。
  • 个体水平变化≥5.5分可视为有意义改善,≥9.1分超出测量误差。
  • 组水平变化≥8.1分可视为有意义改善。
  • 根据治疗类型关注眼肌或全身症状的差异化变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study responsiveness and meaningful change of the Myasthenia Gravis Impairment Index (MGII) and its relative efficiency compared to other measures. METHODS: We enrolled 95 patients receiving prednisone, IV immunoglobulin (IVIg), or plasma exchange (PLEX) and 54 controls. Patients were assessed with the MGII and other measures-including the Quantitative Myasthenia Gravis Score, Myasthenia Gravis Composite, and Myasthenia Gravis Activities of Daily Living-at baseline and 3-4 weeks after treatment. Statistical markers of responsiveness included between-groups and within-group differences, and we estimated the relative efficiency of the MGII compared to other measures. Patient-meaningful change was assessed with an anchor-based method, using the patient's impression of change. We determined the minimal detectable change (MDC) and the minimal important difference (MID) at the group and individual level. RESULTS: Treated patients had a higher change in MGII scores than controls (analysis of covariance p < 0.001). The ocular domain changed more with prednisone than with IVIg/PLEX (effect size 0.67 and 0.13, analysis of covariance p = 0.001). The generalized domain changed more with IVIg/PLEX than with prednisone (effect size 0.50 and 0.22, analysis of covariance p = 0.07). For the total MGII score, the individual MDC95 was 9.1 and the MID was 5.5 for individuals and 8.1 for groups. Relative efficiency ratios were >1 favoring the MGII. CONCLUSIONS: The MGII demonstrated responsiveness to prednisone, IVIg, and PLEX in patients with myasthenia. There is a differential response in ocular and generalized symptoms to type of therapy. The MGII has higher relative efficiency than comparison measures and is viable for use in clinical trials.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Barnett C, Bril V, Kapral M, et al. Myasthenia Gravis Impairment Index: Responsiveness, meaningful change, and relative efficiency. Neurology. 2017. PMID: 29101274. doi:10.1212/WNL.0000000000004676

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。